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ABSTRACT
Introduction: Type 2 diabetes mellitus (T2DM) 
is a complex disease with a number of metabolic 
abnormalities. At present, treatment typically 
proceeds in a stepwise fashion, beginning 
with diet and exercise followed by incremental 
additions of oral antidiabetic agents as required 
to achieve and maintain glycemic control 
(glycosylated hemoglobin [HbA1c] ≤6.9% and 
6.5%, respectively). This approach is reactive 
rather than proactive as progression to the next 
level is based on treatment failure (i.e., not 
achieving target HbA1c levels). Newer approaches 
to treatment of T2DM advocate early use of 
combination antihyperglycemic regimens with 
complementary mechanisms of action to correct 
multiple pathophysiologic defects, but this can 
impact negatively on treatment adherence. 
Fixed-dose combinations are associated 
with higher compliance rates than therapy 
with individual components administered 
concomitantly. This review examines evidence 
for a fixed-dose combination of alogliptin 
and pioglitazone recently approved for use in 
Japanese patients with T2DM.
Methods: A MEDLINE search identified five 
randomized, controlled trials in which alogliptin 
and pioglitazone were used in combination to 
treat T2DM, and these form the basis of the review. 
Results: One study evaluated alogliptin-
pioglitazone combination therapy in drug-naïve 
patients. In the remaining studies, alogliptin 
was evaluated as add-on therapy in patients 
with inadequate glycemic control despite 
treatment with pioglitazone (± metformin 
or sulfonylurea). In all studies, alogliptin-
pioglitazone combination therapy consistently 
produced statistically significant reductions 
in HbA1c of approximately 0.6–1.0% over and 
above those produced by either agent alone. This 
improvement was paralleled by improvements in 
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fasting plasma glucose, proportions of patients 
achieving target HbA1c levels and several other 
measures of glycemic control, including markers 
of beta-cell function. The alogliptin-pioglitazone 
combination was well tolerated across all studies. 
Conclusion: Alogliptin-pioglitazone combination 
therapy represents a rational approach to 
treatment of T2DM as the complementary 
mechanisms target several aspects of impaired 
glucose control. The fixed-dose combination 
offers scope for enhanced patient compliance 
and improved treatment outcomes. 
Keywords: Alogliptin; Beta-cell function; 
Combination therapy; Fixed-dose combinations; 
Glycosylated hemoglobin; Pioglitazone; Type 2 
diabetes mellitus 
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a disorder of 
blood glucose control that arises from multiple 
metabolic abnormalities: impaired response of 
liver and peripheral (muscle, adipose) tissues to 
the effects of insulin (i.e., insulin resistance); 
progressive loss of pancreatic beta-cell function 
(insufficient insulin secretion, reduced beta-cell 
sensitivity to glucose, decreased beta-cell mass); 
dysregulation of glucagon secretion; and altered 
incretin hormone physiology (Fig. 1) [1]. These 
defects all lead to high levels of postprandial and 
fasting blood glucose. 
Early and effective treatment of T2DM is 
essential to minimize the microvascular and 
macrovascular complications associated with 
chronic hyperglycemia, but success remains 
limited. Only about half of patients with T2DM 
in the United States (US) achieve the American 
Diabetes Association glycosylated hemoglobin 
(HbA1c) goal of <7.0% [2] and the proportion 
decreases as the HbA1c target becomes more 
aggressive. A cross-sectional survey involving 
>17,000 patients in Japan found that just over 
one-third (36.8%) achieved the HbA1c target goal 
of <6.9% as recommended by the Japan Diabetes 
Society [3]. 
Hyperglycemia
Peripheral insulin resistance Increased hepatic glucose production
Decreased incretin eect Progressive loss of beta-cell function;
decreased insulin secretion
Impaired glucagon secretion
Fig. 1  Major pathophysiological features of type 2 diabetes mellitus
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Treatment of T2DM typically begins with 
diet/exercise followed by incremental additions 
of single antidiabetic agents as required, most 
commonly metformin or a sulfonylurea to 
achieve and maintain glycemic control. This 
approach is reactive rather than proactive 
as progression to the next level is based on 
treatment failure. Treatment by single oral 
agents are unable to address all the metabolic 
abnormalities that underlie T2DM and the ability 
to treat aggressively is often limited by dose-
dependent side effects [4]. As T2DM progresses, 
most patients require the addition of one or 
more antidiabetic agents to regain glycemic 
control. Combining agents with complementary 
mechanisms of action is a rational approach 
to addressing multiple defects in glycemic 
control with the potential of achieving additive 
clinical benefits [5]. However, multi-drug 
therapy can have a negative impact on patient 
adherence to treatment, particularly in the 
case of chronic diseases, such as T2DM [6–9]. 
Accordingly, interest is growing in the use of 
fixed-dose combinations of antidiabetic agents 
which are not only more convenient for 
patients, but also have the potential to improve 
adherence [10]. Many such combinations 
are possible, but one of considerable interest 
involves the dipeptidyl peptidase-4 (DPP-4) 
inhibitor and thiazolidinedione (TZD) classes 
of oral antidiabetic agents. DPP-4 inhibitors (or 
‘gliptins’) act primarily by increasing pancreatic 
insulin secretion in response to nutrient 
intake [11, 12], whereas TZDs act predominantly 
by improving the sensitivity of muscle and 
adipose tissue to insulin [13]. By addressing two 
of the fundamental defects in T2DM – namely, 
beta-cell dysfunction and insulin resistance 
– this combination offers scope for additive 
efficacy. 
An alogliptin-pioglitazone fixed-dose 
combination tablet was recently approved in 
Japan for use in patients with T2DM. This review 
examines in more detail the pharmacologic 
rationale for combining DPP-4 inhibitors and 
TZDs. In particular, this review focuses on clinical 
trials in which alogliptin and pioglitazone have 
been used in combination for the treatment of 
Japanese patients with T2DM.
METHODS
A MEDLINE search was performed using the 
key words “alogliptin” and “pioglitazone” to 
identify relevant articles for inclusion. A total 
of five randomized, controlled clinical studies 
of alogliptin-pioglitazone combination therapy 
up to and including May 2012 were identified 
and form the basis of this review. These studies 
were supplemented by major reviews and other 





Pioglitazone is a potent insulin sensitizer.
It binds specifically to the peroxisome proliferator-
activated receptor gamma (PPARG) and enhances 
the sensitivity of liver, muscle, and adipose tissue 
to insulin (promoting the uptake of glucose into 
tissues), with a resulting decline in fasting and 
postprandial plasma glucose levels [14, 15]. 
Pioglitazone also increases serum high-density 
lipoprotein (HDL)-cholesterol and decreases 
neutral fat [13], whilst increasing the expression 
and differentiation of adiponectin, a hormone 
that enhances insulin sensitivity [16, 17]. 
Several long-term (>1.5 years), double-blind, 
active comparator studies have consistently 
demonstrated that pioglitazone produces 
a durable decrease in HbA1c levels [18–22],
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a result which can be explained only by its 
ability to improve and preserve beta-cell function 
in patients with T2DM [23]. In other studies 
involving patients with T2DM, pioglitazone was 
shown to reduce the inflammatory response to a 
glucose challenge more than acarbose [24] and 
it was shown to be better than glibenclamide 
in mitigating variations in lipid parameters and 
inflammatory markers [25]. 
Pioglitazone is well absorbed after oral 
administration and reaches maximum 
concentrations in approximately 1.5 h [26]. 
Although metabolized by the hepatic cytochrome 
P450 enzyme system, there is no evidence to 
suggest that pioglitazone inhibits or induces 
any of the P450 isoenzymes involved in drug 
metabolism [27, 28]. The half-life of pioglitazone 
is approximately 9 h, but its glucose-lowering 
activity is extended by two active metabolites. The 
pharmacokinetic characteristics of pioglitazone 
are not significantly altered in patients with 
T2DM, renal or hepatic insufficiency, or in the 
elderly. Pioglitazone can be administered once 
daily without regard to meals [26]. 
Alogliptin
Alogliptin is a potent and highly selective 
inhibitor of DPP-4, the enzyme responsible for 
rapid inactivation of the incretin hormones, 
glucagon-like peptide-1 (GLP-1) and glucose 
dependent insulinotropic polypeptide (GIP) [12]. 
GLP-1 and GIP are secreted in the intestine in 
response to food intake and stimulate insulin 
secretion from pancreatic beta cells in a glucose-
dependent manner. GLP-1 also suppresses 
glucagon secretion and enhances pancreatic 
beta-cell mass through increases in proliferation 
and decreases in apoptosis [1]. GLP-1 has been 
shown to lower glucose levels even in patients 
with severe beta-cell impairment, presumably 
as a result of lowered glucagon levels and other 
non-insulin related effects [29]. By preventing 
the degradation of GLP-1 (and GIP), alogliptin 
restores these endogenous hormones to normal 
physiological levels and extends their half-lives; 
thereby assisting in the maintenance of normal 
plasma glucose levels. The effects of alogliptin 
are observed predominantly after meals [30, 31]. 
Alogliptin is rapidly absorbed after oral 
administration and reaches maximum plasma 
concentration in approximately 1–2 h. It has 
a mean half-life of 12–24 h [1, 31]. Alogliptin 
is only minimally metabolized and is excreted 
primarily unchanged in the urine (75%), 
necessitating dosage adjustments in renal but not 
hepatic impairment [31]. As alogliptin is neither 
an inhibitor nor an inducer of cytochrome P450 
isoforms, there is a low likelihood of drug–
drug interactions [32]. In multiple dose studies 
(14 days) of alogliptin, plasma DPP-4 activity 
was inhibited by >80% after 24 h, supporting 
once-daily dosing [31]. 
Alogliptin-Pioglitazone Combination
Pharmacokinetic studies in healthy volunteers 
indicated no clinically significant changes in the 
area under the curve of the drug concentration-
time profile (AUC0–24 h), maximum concentration 
(Cmax), or time to Cmax (Tmax) for alogliptin or 
pioglitazone, or in urine pharmacokinetic 
parameters for alogliptin, for the combination of 
alogliptin and pioglitazone compared with each 
agent administered alone [33]. 
Animal models of T2DM have demonstrated 
beneficial and additive effects with the alogliptin-
pioglitazone combination on several measures 
of glycemic control compared with either agent 
alone; thus, providing a strong argument for 
clinical use of this specific combination. In ob/ob
mice and db/db mice, combined administration 
of alogliptin and pioglitazone for approximately 
4 weeks significantly improved glycemic control 
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and lipid profiles compared with alogliptin 
or pioglitazone monotherapy [34, 35]. The 
alogliptin-pioglitazone combination also 
increased pancreatic insulin content [34–36], 
maintained islet structure [34], and preserved 
islet mass [36] to a greater extent than either 
agent alone.
CLINICAL EVIDENCE FOR 
ALOGLIPTIN-PIOGLITAZONE 
COMBINATION
Several well-controlled studies have investigated 
alogliptin in combination with pioglitazone 
in the treatment of T2DM patients with 
different clinical presentations: alogliptin-
pioglitazone combination in drug-naïve 
patients [37]; alogliptin as a second or third 
“add-on” oral antidiabetic agent in patients 
being treated with pioglitazone (± metformin 
or sulfonylurea) [38–40]; alogliptin-pioglitazone 
combination in patients being treated with 
metformin [41]. All studies were randomized and 
controlled, with double-blind phases ranging 
from 12 to 52 weeks in duration. Treatment 
(either single component or combination) was 
administered once daily. Patients had baseline 
HbA1c levels of between 6.9% and 11% (mean 
approximately 8% in most studies; 8.8% in 
drug-naïve patients). The primary efficacy 
endpoint in all studies was the change in HbA1c
from baseline to study end. Secondary efficacy 
endpoints included changes from baseline in 
fasting plasma glucose (FPG); proportions of 
patients achieving specific HbA1c target levels; 
incidence of hyperglycemic rescue; changes 
from baseline in markers of beta-cell function 
and insulin resistance, serum lipids, and 
body weight. Safety was assessed according to 
adverse events (AEs), clinical laboratory tests, 
electrocardiograms, physical examinations, vital 
signs, and the incidence of hypoglycemia. 
In drug-naïve patients with T2DM 
inadequately controlled by diet and exercise 
(n = 655), alogliptin plus pioglitazone at two 
different dosage levels (alogliptin 12.5 mg + 
pioglitazone 30 mg [A12.5 + P30]; alogliptin 
25 mg + pioglitazone 30 mg [A25 + P30]) were 
compared with each individual component 
as monotherapy (alogliptin 25 mg [A25]; 
pioglitazone 30 mg [P30]) [37]. For almost all 
efficacy parameters, A25 + P30 was slightly 
but consistently superior to A12.5 + P30, 
and was significantly superior to A25 or P30 
alone. The A25 + P30 combination produced a 
significantly larger reduction from baseline in 
HbA1c (Table 1) [37–41]. Compared with other 
treatment regimens, the A25 + P30 combination 
was also associated with a significantly larger 
reduction from baseline in FPG (–2.8 mmol/L), 
a greater proportion of patients achieving 
the target HbA1c of ≤7.0% (63%), and fewer 
episodes of marked hyperglycemia (25%). 
Fewer patients treated with the alogliptin-
pioglitazone combination at either dose required 
hyperglycemic rescue during the course of the 
26-week trial compared with those receiving 
alogliptin or pioglitazone monotherapy. 
Combination therapy was consistently more 
effective than component monotherapy 
irrespective of age, gender, race, ethnicity, or 
body mass index (BMI). Although the incidence 
of study drug-related adverse effects was highest 
with the A25 + P30 combination (21.3%), there 
was no obvious pattern among treatment arms 
with respect to the number of serious AEs or 
treatment discontinuations due to AEs. Mean 
body weight was increased to a similar extent 
in groups treated with pioglitazone either as 
monotherapy or in combination with alogliptin 
(2.2, 2.5, and 3.1 kg for P30 alone, A12.5 + P30, 
and A25 + P30, respectively), whereas it remained 
virtually unchanged (–0.3 kg) in the group 
treated with A25 monotherapy.
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glycemic control with a TZD (pioglitazone or 
rosiglitazone) with or without concomitant 
metformin or sulfonylurea [38]. Prior to 
randomization, patients previously treated with 
rosiglitazone were switched to an equivalent 
In a large international study encompassing 
125 sites in four world regions, the efficacy 
and safety of alogliptin as add-on therapy 
was investigated in patients with T2DM 
(n = 493) who had failed to achieve adequate 
Table 1  Clinical studies of alogliptin-pioglitazone combination treatment in patients with type 2 diabetes mellitus: mean 
change in HbA1c level from baseline to study end (primary efficacy variable)
Reference Duration Design Population Treatment Change P-value
 (weeks)  characteristics  from baseline
     in HbA1c (%) 
Rosenstock 26 r, db, pg Drug-naïve (n = 655) A25 –0.96  
et al. [37]   Baseline HbA1c 7.5–11% P30 –1.15  
   (mean 8.8%) A12.5 + P30 –1.56 P < 0.05 vs. P30
    A25 + P30 –1.71 P < 0.05 vs. P30 
      and A25
Pratley 26 r, mc, db, pc Inadequate glycemic  PLA + P –0.19   
et al. [38]   control with a TZD (30 or 45)   
   (± metformin or A12.5 + P –0.66 P < 0.001 vs. 
   sulfonylurea) (n = 493) (30 or 45)  PLA + P 
   Baseline HbA1c 7–10% A25 + P –0.80 P < 0.001 vs. 
   (mean 8.0%) (30 or 45)  PLA + P
Kaku 12  r, db, pc +  Inadequate glycemic PLA + P –0.19 P < 0.0001 vs.  
et al. [39]  40 weeks’ control with pioglitazone (15 or 30)  PLA + P 
  open-label (n = 339) A12.5 + P –0.91   
  extension Baseline HbA1c (15 or 30)   
   6.9–10.4% (mean 7.9%) A25 + P –0.97 P < 0.0001 vs. 
    (15 or 30)  PLA + P
Bosi 52 r, db, pg Inadequate glycemic M + P30 +  –0.70 P < 0.001 vs.  
et al. [40]   control with metformin A25  M + P45 
   + pioglitazone (n = 803) M + P45 –0.29
   Baseline HbA1c 
   ≥7.0–≤10.0% (mean 8.3% 
   for M + P30 + A25 and 
   8.1% for M + P45) 
DeFronzo 26 r, mc, db,  Inadequate control with P (15, 30,  –0.9  
et al. [41]  pc, pg metformin (≥1,500 mg) or 45)     
   (n = 1,554) A12.5 + P  –1.4 P < 0.001 vs. P 
    (15, 30, or 45) 
    A25  + P –1.4 P < 0.001 vs. P 
    (15, 30, or 45)
A alogliptin (mg), db double-blind, HbA1c glycosylated hemoglobin (NGSP value), M metformin, mc multicentre, 
P pioglitazone (mg), pc placebo-controlled, pg parallel group, PLA placebo, r randomized, TZD thiazolidinedione
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dosage of pioglitazone (P30 or 45 mg) to which 
placebo or A12.5 or 25 mg (A25) was added. 
Patients also taking metformin or sulfonylurea 
were allowed to continue these medications at 
the same dosage throughout the study. After 
26 weeks’ treatment, the mean change from 
baseline in HbA1c was significantly greater 
with add-on A12.5 or A25 than with placebo 
(Table 1); changes during the course of the study 
were independent of age, BMI, or ethnicity. 
Significantly more patients treated with either 
dose of add-on alogliptin achieved an HbA1c
of ≤7.0% (P = 0.016) and had a reduction in 
HbA1c of ≥1.0% (P < 0.001) compared with 
their placebo-treated counterparts, whereas 
significantly fewer alogliptin- than placebo-
treated patients had marked hyperglycemia 
(P < 0.001). Improvements were statistically 
significant at the first assessment and at each 
subsequent measurement throughout the 
26-week treatment period. Likewise, FPG levels 
decreased with add-on A12.5 or A25 within a 
week of treatment, and remained significantly 
lower than those produced by placebo 
throughout the study. At week 26, there were 
no significant differences between groups in 
terms of changes from baseline in body weight 
(increase of approximately 1 kg in each group) 
or plasma lipid concentrations. With regard 
to safety, the incidence of the most common 
AEs (i.e., those reported by >5% of patients) 
was broadly similar across all three treatment 
groups. More cardiac disorders occurred in 
the A25 group than in the A12.5 and placebo 
groups, but only 2 of 13 reported events were 
considered possibly drug related and both 
were of moderate intensity. Overall, a similar 
proportion of patients (approximately 18%) in 
each group experienced at least one treatment-
related AE and approximately 3% in each 
group discontinued treatment because of an AE 
(Fig. 2) [35]. 
The efficacy and safety of add-on alogliptin 
were also evaluated in a study conducted in 
Japanese patients with inadequate glycemic 
control (HbA1c 6.9–10.4%) whilst being treated 
with pioglitazone and diet/exercise [39]. Patients 
were initially randomized to receive placebo or 
A12.5 or A25 in addition to their existing stable 
dose of pioglitazone 15 mg or P30. After the 
12-week double-blind phase, patients could 
enter a 40-week open-label extension phase 
intended to assess the combination of alogliptin 
plus pioglitazone over the longer term. Of
460 enrolled patients, 339 were randomized in 
the double-blind phase. Similar to the study of 
Pratley et al. described above [38], both doses 
of alogliptin produced significant reductions in 
HbA1c over placebo when added to pioglitazone 
(Table 1), and these were independent of age, 
gender, or duration of diabetes. A significantly 
greater proportion of patients treated with 
alogliptin than placebo achieved HbA1c levels 
of <6.9% (approximately 50% with either 
dose vs. 20% with placebo). Mean changes 
from baseline in a range of other glycemic/
metabolic parameters further demonstrated the 
superiority of add-on alogliptin over placebo 




















≥ AE resulting in study
discontinuation
Fig. 2  Incidence of treatment-related AEs and study 
discontinuations due to AEs in patients with T2DM treated 
with add-on PLA, A12.5, or A25 to PIO ± metformin or 
sulfonylurea [35].  A alogliptin (mg), AE adverse event,  
PIO pioglitazone, T2DM type 2 diabetes mellitus
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A12.5 or A25 were associated with significantly 
greater mean changes from baseline in FPG 
levels, glycoalbumin, proinsulin:insulin ratio, 
homeostasis model assessment of beta-cell 
function (HOMA-beta), and serum lipids. 
Both doses of add-on alogliptin also produced 
significant decreases in postprandial blood 
glucose levels and concentrations of active GLP-
1, but did not increase the risk of hypoglycemia 
compared with placebo. The beneficial effects 
of alogliptin add-on therapy on measures of 
glycemic control were maintained throughout 
the 52-week treatment period. Specifically, 
significant improvements from baseline in 
HOMA-beta and the proinsulin:insulin ratio, 
both markers of beta-cell function, were 
observed at all assessment points in the add-on 
alogliptin groups. Consistent with its lack of 
effect on insulin resistance, alogliptin had 
no significant effect on homeostasis model 
assessment of insulin resistance (HOMA-R). 
Add-on alogliptin was generally well tolerated 
with no dose-related differences in the incidence 
of adverse effects. During the extension phase, 
the only drug-related AE with an incidence of 
≥3% was edema (3% in the A25 group vs. 1.2% 
in the A12.5 group), but this was generally mild 
and is likely to have been related to pioglitazone. 
Alogliptin has also been investigated as 
a third oral antidiabetic drug in patients 
failing to achieve adequate glycemic control 
whilst receiving combination treatment with 
metformin (≥1,500 mg or maximum tolerated 
dose) and P30 [40]. This study compared the 
efficacy and safety of adding A25 to a submaximal 
dose of pioglitazone versus up-titrating the 
pioglitazone dose to 45 mg. As with all other 
studies described above, greater improvement 
in measures of glycemic control was noted with 
the addition of alogliptin. After 52 weeks of 
treatment, the mean decrease in HbA1c levels 
was –0.70% with metformin + P30 + A25 as 
compared with –0.29% in the group treated with 
metformin and pioglitazone 45 mg (Table 1), 
and efficacy was independent of gender, age, 
race, ethnicity, and baseline BMI. Alogliptin 
add-on therapy produced significantly (P < 0.01) 
greater decreases in FPG at all time points and 
significantly more patients receiving add-on 
alogliptin achieved an HbA1c of ≤7.0% compared 
Table 2  Changes from baseline in several glycemic/metabolic parameters in Japanese patients treated for 12 weeks with add-
on PLA or alogliptin (A12.5 or A25) to pioglitazone (P15 or P30) [39]
 PLA + P  A12.5 + P A25 + P 
 (n = 115)  (n = 111)  (n = 113)
Fasting plasma glucose (mg/dL) –2.4 –14.9* –18.9*
Glycoalbumin (%) –0.11 –2.73* –2.79*
DPP-4 activity (nmol/min/mL) 0.24 –9.63* –10.01*
HOMA-R –0.11 –0.14 –0.20
HOMA-beta (%) 0.06 5.48* 6.99*
Body weight (kg) –0.03 0.48* 0.46*
Blood glucose 2-h (mg/dL) during meal tolerance test –4.5 –31.8* –41.5*
Active GLP-1 AUC0-2h (pmol·h/L) during meal tolerance test 0.9 10.3* 11.4*
Total cholesterol (mg/dL) 0.3 –4.5 –5.7*
* P < 0.05 versus PLA + P
A alogliptin (mg), AUC0-2h area under the blood glucose concentration time curve from 0 h to 2 h, DPP-4 dipeptidyl 
peptidase 4, GLP-1 glucagon-like peptide-1, HOMA-R homeostasis model assessment of insulin resistance, HOMA-beta 
homeostasis model assessment of beta-cell function, P pioglitazone (mg), PLA placebo
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with the pioglitazone up-titration group (33.2% 
vs. 21.3%; P < 0.001). In parallel with the 
findings of Kaku et al. in Japanese patients [39], 
significant improvements (P < 0.001) in the 
proinsulin:insulin ratio and HOMA-beta were 
noted with metformin + P30 + A25 compared 
with metformin and pioglitazone 45 mg at 
week 52, whereas no statistically significant 
differences from baseline were seen between 
treatment groups for C-peptide concentrations, 
HOMA-R, and serum lipids. Approximately 
twice as many patients treated with metformin 
and pioglitazone 45 mg than with metformin 
+ P30 + A25 (87 vs. 44; P < 0.001) discontinued 
treatment because of the need for hyperglycemic 
rescue. The most common drug-related AE was 
peripheral edema, which was experienced by 
eight patients (2.0%) in the metformin + P30 
+ A25 group and by 12 patients (3.0%) in the 
metformin and pioglitazone 45 mg group. 
Lastly, the efficacy and tolerability of 
alogliptin in combination with pioglitazone were 
evaluated in patients with T2DM inadequately 
controlled by maximum doses (≥1,500 mg) 
of metformin monotherapy [41]. The study 
contained 12 treatment groups: placebo; A12.5 
or A25; pioglitazone at doses of 15, 30, or 45 mg; 
and A12.5 and A25 in combination with one 
of the three doses of pioglitazone. The primary 
analyses compared pioglitazone monotherapy 
(all doses pooled, n = 387) with A12.5 plus any 
dose of pioglitazone (A12.5 + pioglitazone; 
n = 390) or A25 plus any dose of pioglitazone 
(A25 + pioglitazone; n = 390). Combined with 
any dose of pioglitazone, both doses of alogliptin 
produced durable reductions in HbA1c that 
were greater than those produced by any dose 
of pioglitazone alone. At week 26, the change 
from baseline in HbA1c was –1.4% for both 
A12.5 + pioglitazone and A25 + pioglitazone, 
compared with –0.9% for pioglitazone alone 
(both comparisons P < 0.001) (Table 1).
Again, no differences in efficacy were observed 
for any predefined patient subgroup based on 
gender, age, race, ethnicity, or baseline BMI. 
Approximately 55% of patients treated with 
the alogliptin and pioglitazone in combination 
achieved an HbA1c of ≤7.0%. The alogliptin-
pioglitazone combination also produced 
greater reductions in FPG (–2.5 mmol/L for 
both alogliptin doses) than pioglitazone alone 
(–1.6 mmol/L; P < 0.001), and fewer patients 
receiving the combination therapy required 
hyperglycemic rescue (1.5–4.6%) than those 
treated with either component alone (8.5–14.7%) 
or placebo (31.8%). Both A12.5 + pioglitazone 
and for A25 + pioglitazone produced significantly 
greater improvement in measures of beta-cell 
function (proinsulin:insulin ratio and HOMA-
beta) than pioglitazone alone, but had no obvious 
additive effect on HOMA-R. There was a weight 
gain of between 1.5 kg and 1.9 kg in groups 
treated with pioglitazone either as monotherapy 
or in combination, and alogliptin neither 
prevented nor exacerbated this weight gain. All 
regimens were well tolerated; hypoglycemia was 
uncommon and generally mild-to-moderate in 
severity, although two severe cases were reported 
when alogliptin was added to pioglitazone 
and metformin [40]. Relative to pioglitazone 
monotherapy,  a logl ipt in-piogl i tazone 
combination therapy was not associated with any 
meaningful differences in weight gain, incidence 
of hypoglycemia, AEs, serious AEs, or treatment 
discontinuations due to an AE. 
DISCUSSION
The treatment of T2DM has long encompassed 
a stepwise approach beginning with diet and 
exercise and an oral antihyperglycemic agent, 
followed by the addition of one or more 
agents as required in the event that glycemic 
control deteriorates. This approach is reactive 
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rather than proactive as it is based around 
compensating for the progressive decline of beta-
cell function that underlies the deterioration in 
glycemic control. It is now known that beta-cell 
failure occurs much earlier and is more severe 
than previously thought (>80% failure at the 
time of diagnosis) [22], suggesting that a newer 
approach to T2DM treatment is warranted. In 
a Banting Lecture [23], DeFronzo called for a 
paradigm shift in the management of T2DM 
based on the following principles.
1. Effective treatment of T2DM requires 
multiple drugs used in combination to 
correct multiple pathophysiological defects.
2. Treatment should be based on known 
pathogenic abnormalities and not simply 
on reduction of HbA1c.
3. Therapy must be started early in the natural 
history of T2DM to prevent progressive 
beta-cell failure.
The combination of alogliptin and pioglitazone 
appears to address these more modern 
requirements for treatment of T2DM as these 
agents work by complementary mechanisms; 
alogliptin increases insulin secretion and 
decreases glucagon secretion after meals [11, 12], 
whereas pioglitazone increases both peripheral 
and hepatic insulin sensitivity [13]. In an 
animal model of T2DM, the combination of 
alogliptin and pioglitazone administered at an 
early stage of diabetes was shown to improve 
beta-cell function and maintain islet structure 
to a greater extent than either component as 
monotherapy [34]. 
Randomized controlled trials in which 
combination therapy with alogliptin and 
pioglitazone was investigated clinically in 
patients with T2DM provide strong and 
consistent clinical evidence for the efficacy of this 
particular combination. In these trials, alogliptin 
combined with pioglitazone was evaluated within 
the framework of several typical T2DM treatment 
backgrounds: alogliptin-pioglitazone as initial 
therapy in drug-naïve patients [37]; alogliptin as 
add-on treatment to pioglitazone (± metformin 
or sulfonylurea) [38, 39]; alogliptin as add-on 
treatment to pioglitazone + metformin [40]; and 
alogliptin-pioglitazone as add-on treatment to 
metformin [41]. The double-blind phase of these 
studies ranged from 12 to 52 weeks in duration, 
providing a reasonable estimate of the safety and 
tolerability of the combination over a longer 
term. 
Irrespective of patients’ previous and current 
exposure to antidiabetic drugs, alogliptin 
and pioglitazone given in combination 
was superior to any other study regimen as 
regards the reduction in HbA1c levels (primary 
efficacy measure) and secondary measures of 
glycemic control. From a typical mean baseline 
HbA1c of approximately 8.0%, the alogliptin 
and pioglitazone in combination produced 
statistically significant reductions of between 
0.6% and 1.0% over and above those produced by 
either agent alone (± metformin or sulfonylurea). 
In parallel, significantly greater proportions 
of patients treated with combination therapy 
achieved target HbA1c levels as defined per study 
(generally ≤7.0%). In all studies, responder 
analyses according to prespecified subgroups 
showed no differences in efficacy based on age, 
gender, baseline BMI, duration of diabetes, or 
ethnicity, indicating that the combination can 
be used across the T2DM patient spectrum. All 
studies reported significantly greater reductions 
in FPG with alogliptin-pioglitazone combination 
therapy. Importantly, the combination 
of alogliptin and pioglitazone (± another 
antidiabetic agent) consistently produced greater 
improvements in measures of beta-cell function 
(i.e., HOMA-beta function and proinsulin:insulin 
ratio) than study regimens in which these two 
agents were not combined [38–40], suggestive of 
an additive effect. 
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Across all studies, the alogliptin and 
pioglitazone combination therapy was well 
tolerated. No new safety issues emerged with the 
combination outside of the known or potential 
adverse effects of each individual component. 
Hypoglycemia was uncommon and generally 
mild-to-moderate in severity, although two 
severe cases were reported when alogliptin was 
added to pioglitazone and metformin [40]. 
Consistent with the known adverse effects 
of TZD, pioglitazone was associated with 
an increase in body weight [37, 38, 40] but 
alogliptin appeared to be weight-neutral as it 
neither prevented nor exacerbated weight gain. 
It can be concluded from these results that the 
alogliptin-pioglitazone combination successfully 
meets the more modern requirements for 
treatment of T2DM as outlined above [23] and 
represents a rational approach to the treatment 
of T2DM. The complementary mechanisms 
of action of alogliptin and pioglitazone 
address several of the underlying metabolic 
abnormalities in patients with T2DM. The 
efficacy of this specific combination extends 
beyond that of reducing HbA1c levels to include 
improvements in several other measures of 
glycemic control. Importantly, the ability of 
the alogliptin-pioglitazone combination to 
preserve beta-cell function offers a degree of 
promise in terms of slowing or halting the 
progression of disease. Should this be confirmed 
with longer-term use, it is anticipated that 
alogliptin-pioglitazone combination treatment 
may offer value when given early in the course 
of T2DM. The clinical benefits of combining a 
DPP-4 inhibitor with pioglitazone for improving 
glycemic control in patients with T2DM has also 
been documented for other agents in this class, 
such as vildagliptin [42], sitagliptin [43–45], 
saxagliptin [46], and linagliptin [47].
The introduction of the fixed-dose 
combination alogliptin and pioglitazone in Japan 
is relatively recent and future investigations 
should investigate its clinical efficacy and safety 
relative to other combinations of antidiabetic 
drugs in patients with T2DM. Given the 
high rate of co-existing medical conditions 
in patients with T2DM it is also important to 
assess the impact of the combination on clinical 
outcomes, including cardiovascular outcomes in 
patients at risk. In this regard, the Examination 
of cArdiovascular outcoMes with alogliptin 
versus standard carE in patients with type 2 
diabetes mellitus and acute coronary syndrome 
(EXAMINE) study is planned to include >5,000 
men and women with T2DM and acute coronary 
syndrome, and who will receive alogliptin or 
placebo for up to 4.5 years in a well-controlled 
randomized trial [48].
Simplification of drug administration via 
the convenience of an alogliptin-pioglitazone 
fixed-dose combination tablet provides the 
opportunity to improve compliance over 
that which can be achieved by concomitant 
treatment with the individual constituents 
and while maximally exerting the intended 
antihyperglycemic effect; thereby potentially 
enhancing treatment efficacy and clinical 
outcomes. 
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